Glycerophosphate De Sodium

Glycerophosphate De Sodium is a sterile aqueous solution for injection that contains sodium glycerophosphate pentahydrate as its active ingredient. It is supplied in a standard concentration for intravenous use and is marketed in the European Union. The product provides a readily bioavailable source of phosphate for patients requiring parenteral nutrition. Each vial typically contains 0.5 g of the pentahydrate dissolved in 100 mL of isotonic solution, allowing precise dosing in clinical settings.

Glycerophosphate De Sodium is primarily used to supplement phosphate in patients receiving parenteral nutrition when oral intake is insufficient or contraindicated.

- Provides inorganic phosphate for cellular metabolism and bone mineralization. - Supports energy production through ATP synthesis in critically ill patients. - Helps maintain acid‑base balance by acting as a buffer in intravenous solutions. - Used in neonatal and pediatric intensive care where phosphate requirements are high. - Can be incorporated into customized total parenteral nutrition (TPN) admixtures. - Facilitates renal phosphate reabsorption when administered with appropriate electrolyte balance.

Adverse reactions to Glycerophosphate De Sodium are generally infrequent, but they may occur depending on patient condition and infusion rate.

Common: - Mild transient hyperphosphatemia that resolves after infusion. - Local irritation at the injection site, such as pain or erythema. - Nausea or mild gastrointestinal discomfort when administered rapidly. - Transient increase in serum calcium due to complex formation.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation and possible renal dysfunction. - Hypocalcemia secondary to rapid phosphate shift. - Allergic reactions ranging from urticaria to anaphylaxis. - Metabolic acidosis if large volumes are infused without appropriate buffering. - Cardiovascular instability such as hypotension or arrhythmia in patients with severe electrolyte disturbances.

When using Glycerophosphate De Sodium, clinicians should observe specific precautions to minimize risks and ensure safe phosphate supplementation.

- Assess baseline serum phosphate, calcium, and renal function before initiation. - Adjust dose in patients with impaired renal clearance to avoid accumulation. - Monitor serum electrolytes regularly during therapy, especially calcium and phosphate levels. - Use caution in patients with hyperparathyroidism or active bone disease. - Avoid rapid infusion rates that may provoke sudden shifts in serum phosphate. - Consider compatibility with other intravenous solutions to prevent precipitation.

Glycerophosphate De Sodium may interact with certain intravenous medications or solutions, influencing electrolyte balance or causing precipitation.

Avoid: - Co‑administration with calcium‑containing solutions without proper mixing protocols, which can precipitate calcium phosphate. - Simultaneous infusion with high‑dose vitamin D analogues that increase calcium absorption, raising risk of hypercalcemia. - Avoid mixing with alkaline solutions that may raise pH and promote precipitation.

Use with caution: - Concurrent use of loop diuretics, as they can alter renal phosphate handling. - Administration alongside parenteral nutrition containing magnesium, requiring electrolyte monitoring. - Use with beta‑agonists that may shift intracellular phosphate. - Monitor cardiac function when combined with drugs that affect calcium signaling, such as digitalis.